The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).
 
Matthew Dallos
No Relationships to Disclose
 
Samuel M Pan
No Relationships to Disclose
 
Matthew Chaimowitz
No Relationships to Disclose
 
Mark N. Stein
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Vaccitech; Xencor
Research Funding - Advaxis (Inst); Bellicum Pharmaceuticals; Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)
 
Emerson A. Lim
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jessica Hawley
Research Funding - Dendreon; Regeneron
Travel, Accommodations, Expenses - Genzyme
 
Naomi Sender
No Relationships to Disclose
 
Sarah Sta Ana
No Relationships to Disclose
 
Karie Runcie
No Relationships to Disclose
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Immunomedics; IMPAC Medical Systems; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Patrick Johnston Mille
No Relationships to Disclose
 
William Kevin Kelly
Honoraria - Janssen Oncology
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Amgen (Inst); Bayer (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Exelixis (Inst); Janssen Oncology (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Merck Sharp & Dohme
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
David M. Nanus
Consulting or Advisory Role - AstraZeneca; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Charles G. Drake
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Oncology; Werewolf Therapeutics
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)